New York, New York-- (Newsfile Corp. - March 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

With Concentra Biosciences expanding its stock influence in Pliant Therapeutics and Acelyrin, the two biotechs have shored up ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

Pliant Therapeutics, Inc. has announced the adoption of a limited duration stockholder rights agreement aimed at protecting shareholder interests in light of recent stock accumulations.

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating reiterated by research analysts at HC ...

Acelyrin and Pliant Therapeutics, both of which are viewed as takeover targets for Kevin Tang’s Concentra Biosciences, each adopted a “poison pill” on Thursday morning.

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration ...